Strategies to improve the tolerability of BETAFERON


 

Over time, lessons learned through clinical experience have improved the safety and tolerability of BETAFERON. As a result, the latest trials have observed a lower incidence rate of interferon beta-typical adverse events compared with earlier studies [1]. Furthermore, interferon beta-typical adverse events such as flu-like symptoms and injection site reactions diminish over time in most patients [2].

 

The following measures may improve safety and/or tolerability of BETAFERON:

  • Dose titration at treatment initiation [3] (See figure for recommended titration scheme)
  • Use of non-steroidal anti-inflammatory drugs [1,3] and administration of BETAFERON in the morning instead of the evening [4] may mitigate flu-like symptoms
  • Use of an autoinjector may reduce injection site reactions [1,3]
  • Use of thinner needles (30 G instead of 27 G) may also help to improve injection site tolerability [5]

 

Alt tag

Recommended titration scheme for BETAFERON [3]

References

  • Lugaresi A et al. Expert Rev Neurother 2014; 14(9): 1029-42. Return to content
  • Kappos L et al. Neurology 2006; 67(7): 1242-9. Return to content
  • BETAFERON® European Summary of Product Characteristics, October 2020. Available at: https://www.ema.europa.eu/en/documents/product-information/betaferon-epar-product-information_en.pdf Return to content
  • Nadjar Y et al. Clin Neurol Neurosurg 2011; 113: 316-22. Return to content
  • Baum K et al. Mult Scler 2007; 13(9): 1153-60. Return to content
Alt tag